Enhancing the Bioavailability of Low-Solubility Compounds
We respect your privacy, by clicking ‘Watch On Demand’ you agree to receive our e-newsletter, including information on Podcasts, Webinars, event discounts and online learning opportunities. For further information on how we process and monitor your personal data click here. You can unsubscribe at anytime.
Low aqueous solubility resulting in poor oral bioavailability of drug candidates is recognised as an increasingly common challenge facing the pharmaceutical industry. An estimated 25% to 30% of compounds in early development have poor bioavailability due to low solubility, representing a significant loss in therapeutic and economic opportunity.
In this complimentary case study webcast, Bend Research discusses amorphous dispersion based formulations highlighting:
- Outlining the need for increased solubility and rapid absorption
- Assessing the impact of enteric dispersions on absorption rate
- Developing rapidly dissolving amorphous formulations
- Pursuing formulation and process development for amorphous drugpolymer nanoparticles
Presenters:
Dana Settell
Director of Business Development
Bend Research, Inc
We respect your privacy, by clicking ‘Watch On Demand’ you agree to receive our e-newsletter, including information on Podcasts, Webinars, event discounts and online learning opportunities. For further information on how we process and monitor your personal data click here. You can unsubscribe at anytime.
